MYCN and central nervous system cancer: The upregulation of MYCN expression was recapitulated by transduction of H3.3G34V into normal human astrocytes and fetal glial cell lines, suggesting that the H3F3A G34V mutation enhances the expression of this oncogene, and that targeting MYCN stability might provide a therapeutic option for the treatment of H3.3 G34 mutant glioma [106].